Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

901 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.
Atkin C, Iqbal G, Planche T, Pratt G, Yong K, Wood J, Raynes K, Low E, Higgins H, Neal RD, Dunn J, Drayson MT, Bowcock S; TEAMM Trial Management Group; Trial Investigators. Atkin C, et al. Among authors: yong k. Br J Haematol. 2021 Mar;192(6):997-1005. doi: 10.1111/bjh.17044. Epub 2020 Aug 15. Br J Haematol. 2021. PMID: 32798327 Free article. Clinical Trial.
T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
D'Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M, White H, Hale G, Waldmann H, Goldstone A, Mackinnon S, Yong K. D'Sa S, et al. Among authors: yong k. Br J Haematol. 2003 Oct;123(2):309-22. doi: 10.1046/j.1365-2141.2003.04612.x. Br J Haematol. 2003. PMID: 14531914 Free article. Clinical Trial.
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Free article. Clinical Trial.
Guidelines for the diagnosis and management of multiple myeloma 2011.
Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J; Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Bird JM, et al. Among authors: yong k. Br J Haematol. 2011 Jul;154(1):32-75. doi: 10.1111/j.1365-2141.2011.08573.x. Epub 2011 May 14. Br J Haematol. 2011. PMID: 21569004 Free article. Review. No abstract available.
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial.
Morris TC, Williams C, Bell S, Fletcher M, Szubert A, Cavenagh J, Snowden J, Ashcroft J, Yong K, Cavet J, Brown J, Cook G; National Cancer Research Institute Haematology Clinical Studies Groups. Morris TC, et al. Among authors: yong k. Br J Haematol. 2013 Nov;163(4):541-3. doi: 10.1111/bjh.12513. Epub 2013 Aug 16. Br J Haematol. 2013. PMID: 24033132 Free article. No abstract available.
901 results